Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic mesenchymal stromal cells (Ottawa Hospital Research Institute)
- Development stage
- Unknown
- Lead developer
- Ottawa Hospital Research Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of allogeneic mesenchymal stromal cells (MSCs) developed by the Ottawa Hospital Research Institute for the treatment of septic shock. The therapy functions as an immunomodulatory biologic that works by dampening systemic inflammation, enhancing the clearance of pathogens, and facilitating tissue repair. The program's initial Phase I trial (CISS) utilized freshly cultured bone marrow-derived MSCs and established the safety and tolerability of the approach at doses up to 3.0 million cells/kg. Following the completion of the Phase I study, the development program progressed to a Phase II trial (UC-CISS II) evaluating cryopreserved umbilical cord-derived MSCs. The cells are produced to clinical-grade standards at The Ottawa Hospital Cell Manufacturing Facility.
- Other names
- allogeneic bone marrow-derived mesenchymal stromal cellsallogeneic umbilical cord-derived mesenchymal stromal cellsMSCs
Beyond the preview
Go deeper on allogeneic mesenchymal stromal cells (Ottawa Hospital Research Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic mesenchymal stromal cells (Ottawa Hospital Research Institute).